Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis
These findings suggest that ravulizumab had the highest probability of being the most superior treatment in decreasing relapse risk in NMO-SD.
Authors
- Andy Lim (ORCID: https://orcid.org/0000-0002-2522-3927)
- L. Zhang
- Nevin John (ORCID: https://orcid.org/0000-0002-9834-4498)
- Thanh G. Phan (ORCID: https://orcid.org/0000-0003-3400-6323)
- Henry Ma (ORCID: https://orcid.org/0000-0002-0510-8059)
- Jen-Chi Cheng
- Victor Chong (ORCID: https://orcid.org/0000-0002-7693-522X)
- Shevita Ram Sunthar
- Julie Boktor
Institutions
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1007/s00415-025-13279-7
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89
Funders
- Monash University